To explore potential pharmaceutical approaches that can effectively target ovarian cancer with high ACTL6A expression, we used the Q-omics analysis (http://qomics.sookmyung.ac.kr/, data obtained on 1 October 2022) to search potent drugs that may act to treat with high ACTL6A expression. Here, ACTL6A is linked to ovarian cancer.